Caenorhabditis Intervention Testing Program - Buck Institute Compound Testing

项目摘要 与人类老龄化相关的健康挑战给我们的社会带来了巨大的损失。身体和认知能力下降 限制老年人及其照顾者的生活质量。衰老是发病的主要风险因素，也是可能的原因 患癌症、糖尿病和神经退行性疾病，并因此与衰弱的疾病作斗争是一种常见的疾病 老龄化人口的健康负担。毫无疑问，促进健康老龄化具有延展性 抵抗衰退应该是当前医学研究的一个主要目标。 为了研究健康的衰老，人们研究了线虫等简单动物模型， 提供对基因和化学化合物干预的分子洞察，这些干预可以调节保守的 衰老过程很可能在人类身上也有类似的作用。拟议工作的目标是继续并扩大， 由三个密切互动的实验室组成的合作科学小组的努力，这些实验室协调进行测试 延长线虫健康衰老和延长寿命的药物干预。一个 这个整合的超级小组特别强调的是在一系列天然变种上测试有前景的药物 线虫属，它们共同代表了人类广泛的遗传异质性 人口。这个想法是，在不同人群中产生积极结果的治疗方法将产生 增加在高等生物体中有效的机会，并将被建议作为优先干预措施 在临床前的小鼠研究中进行测试，可能在未来的人体试验中也是如此。 CITP Buck提案的重点是报告化合物测试的进展情况，以及我们建议的 我们向普通生物医学界开放CITP时的工作流程。 总体而言，我们将参与一个独特的团队项目，该项目有能力定义药理学干预 这有力地促进了不同人群的强大健康寿命，对 促进人类健康衰老的疗法。

Project Summary Health challenges linked to human aging take a tremendous toll on our society. Physical and cognitive decline limit the quality of life for the elderly and their caregivers. Aging is the major risk factor for, and possible cause of cancer, diabetes, and neurodegenerative disease, and thus struggle with debilitating disease is a common health burden for the aging population. Without question, the promotion of healthy aging with extended resistance to decline should be a major objective of current medical research. To investigate healthy aging, simple animals models such as the nematode C. elegans have been studied, providing molecular insights into the genes and chemical compound interventions that can modulate conserved aging processes likely to act similarly in humans. The goal of the proposed work is to continue, and expand, efforts of a co-operative scientific group involving three closely interacting laboratories who coordinately test pharmacological interventions for the ability to extend healthy aging and promote longevity in nematodes. A specific emphasis of this integrated super-group is to test promising drugs on a collection of natural variants of the Caenorhabditis genus, which together represent the extensive genetic heterogeneity in the human population. The idea is that treatments that confer positive outcomes across a diverse population will have an increased chance of being efficacious in higher organisms and will be suggested as priority interventions for testing in pre-clinical mouse studies and possibly future human trials. The emphasis of this CITP Buck proposal is to report on progress in testing compounds and our proposed workflow as we open the CITP to the general biomedical community. Overall, we will participate in a unique team project that has the power to define pharmacological interventions that robustly promote strong healthspan across a varied population, with implications for development of therapies that promote healthy human aging.